ABSTRACT
A high-throughput screening assay was developed and applied to a large library of natural product extract samples, in order to identify compounds which preferentially inhibited the in vitro 2D growth of a highly metastatic osteosarcoma cell line (MG63.3) compared to a cognate parental cell line (MG63) with low metastatic potential. Evaluation of differentially active natural product extracts with bioassay-guided fractionation led to the identification of lovastatin (IC50 = 11 µm) and the limonoid toosendanin (IC50 = 26 nm). Other statins and limonoids were then tested, and cerivastatin was identified as a particularly potent (IC50 < 0.1 µm) and selective agent. These compounds potently and selectively induced apoptosis in MG63.3 cells, but not MG63. Assays with other cell pairs were used to examine the generality of these results. Statins and limonoids may represent unexplored opportunities for development of modulators of osteosarcoma metastasis. As cerivastatin was previously approved for clinical use, it could be considered for repurposing in osteosarcoma, pending validation in further models.
Subject(s)
Biological Products/pharmacology , Cell Proliferation/drug effects , High-Throughput Screening Assays/methods , Biological Products/chemistry , Biological Products/isolation & purification , Bone Neoplasms/metabolism , Bone Neoplasms/pathology , Cell Line , Cell Movement/drug effects , Cell Survival/drug effects , Drugs, Chinese Herbal/chemistry , Drugs, Chinese Herbal/isolation & purification , Drugs, Chinese Herbal/pharmacology , Humans , Lovastatin/chemistry , Lovastatin/isolation & purification , Lovastatin/pharmacology , Melia/chemistry , Melia/metabolism , Monascus/chemistry , Monascus/metabolism , Osteosarcoma/metabolism , Osteosarcoma/pathology , Plant Extracts/chemistry , Pyridines/chemistry , Pyridines/isolation & purification , Pyridines/pharmacology , Seeds/chemistry , Seeds/metabolismSubject(s)
Breast Neoplasms/therapy , Medical Oncology/organization & administration , Animals , Breast Neoplasms/drug therapy , Breast Neoplasms/genetics , Dog Diseases/genetics , Dog Diseases/therapy , Dogs , Drug Evaluation, Preclinical , Female , Humans , Medical Oncology/methods , Neoplasms/therapy , Neoplasms/veterinary , Pets , Veterinary Medicine/organization & administrationABSTRACT
Sarcomas are a rare subgroup of pediatric cancers comprised of a variety of bone and soft-tissue tumors. While significant advances have been made in improving outcomes of patients with localized pediatric sarcomas since the addition of systemic chemotherapy to local control many decades ago, outcomes for patients with metastatic and relapsed sarcoma remain poor with few novel therapeutics identified to date. With the advent of new technologies to study cancer genomes, transcriptomes and epigenomes, our understanding of sarcoma biology has improved tremendously in a relatively short period of time. However, much remains to be accomplished in this arena especially with regard to translating all of this new knowledge to the bedside. To this end, a meeting was convened in Philadelphia, PA, on April 18, 2015 sponsored by the QuadW foundation, Children's Oncology Group and CureSearch for Children's Cancer that brought together sarcoma clinicians and scientists from North America to review the current state of pediatric sarcoma biology and ongoing/planned genomics based clinical trials in an effort to identify and bridge knowledge gaps that continue to exist at present. At the conclusion of the workshop, three key objectives that would significantly further our understanding of sarcoma were identified and a proposal was put forward to develop an all-encompassing pediatric sarcoma biology protocol that would address these specific needs. This review summarizes the proceedings of the workshop.
Subject(s)
Sarcoma/genetics , Translational Research, Biomedical , Animals , Clinical Protocols , Drug Evaluation, Preclinical , Epigenomics , Genomics , Germ-Line Mutation , Humans , Precision Medicine/trends , Recurrence , Sarcoma/pathology , Sarcoma/therapy , Xenograft Model Antitumor AssaysABSTRACT
Despite successful primary tumor treatment, the development of pulmonary metastasis continues to be the most common cause of mortality in patients with osteosarcoma. A conventional drug development path requiring drugs to induce regression of established lesions has not led to improvements for patients with osteosarcoma in more than 30 years. On the basis of our growing understanding of metastasis biology, it is now reasonable and essential that we focus on developing therapeutics that target metastatic progression. To advance this agenda, a meeting of key opinion leaders and experts in the metastasis and osteosarcoma communities was convened in Bethesda, Maryland. The goal of this meeting was to provide a "Perspective" that would establish a preclinical translational path that could support the early evaluation of potential therapeutic agents that uniquely target the metastatic phenotype. Although focused on osteosarcoma, the need for this perspective is shared among many cancer types. The consensus achieved from the meeting included the following: the biology of metastatic progression is associated with metastasis-specific targets/processes that may not influence grossly detectable lesions; targeting of metastasis-specific processes is feasible; rigorous preclinical data are needed to support translation of metastasis-specific agents into human trials where regression of measurable disease is not an expected outcome; preclinical data should include an understanding of mechanism of action, validation of pharmacodynamic markers of effective exposure and response, the use of several murine models of effectiveness, and where feasible the inclusion of the dog with naturally occurring osteosarcoma to define the activity of new drugs in the micrometastatic disease setting.
Subject(s)
Antineoplastic Agents/therapeutic use , Bone Neoplasms/drug therapy , Disease Models, Animal , Drug Evaluation, Preclinical , Osteosarcoma/drug therapy , Animals , Bone Neoplasms/pathology , Disease Progression , Dogs , Humans , Osteosarcoma/secondaryABSTRACT
Immunological synapse (IS) formation involves receptor-ligand pair clustering and intracellular signaling molecule recruitment with a coincident removal of other membrane proteins away from the IS. As microfilament-membrane linkage is critical to this process, we investigated the involvement of ezrin and moesin, the two ezrin/radixin/moesin proteins expressed in T cells. We demonstrate that ezrin and moesin, which are generally believed to be functionally redundant, are differentially localized and have important and complementary functions in IS formation. Specifically, we find that ezrin directly interacts with and recruits the signaling kinase ZAP-70 to the IS. Furthermore, the activation of ezrin by phosphorylation is essential for this process. In contrast, moesin dephosphorylation and removal, along with CD43, are necessary to prepare a region of the cell cortex for IS. Thus, ezrin and moesin have distinct and critical functions in the T cell cortex during IS formation.
Subject(s)
Cytoskeletal Proteins/physiology , Leukosialin/physiology , Microfilament Proteins/physiology , ZAP-70 Protein-Tyrosine Kinase/physiology , Animals , Calcium/metabolism , Cytoskeletal Proteins/genetics , Cytoskeletal Proteins/metabolism , Humans , Jurkat Cells , Leukosialin/metabolism , Lymphocyte Activation/immunology , Microfilament Proteins/genetics , Microfilament Proteins/metabolism , Mutation , Phosphorylation , Precipitin Tests , RNA, Small Interfering/metabolism , Recombinant Proteins/metabolism , Spodoptera/cytology , Spodoptera/metabolism , T-Lymphocytes/physiology , Transfection , ZAP-70 Protein-Tyrosine Kinase/metabolismABSTRACT
Pet dogs with naturally occurring cancers offer a novel opportunity for the study of both cancer biology and therapy. The following review will provide the rationale for the use of these spontaneous cancer models in translational research, particularly in the development of anticancer aerosols. A summary of work involving pet dogs with primary and metastatic cancers to the lung and the investigation of therapeutic chemotherapy and cytokine immunotherapy aerosols will be presented.
Subject(s)
Antineoplastic Agents/administration & dosage , Drug Delivery Systems/methods , Lung Neoplasms/drug therapy , Lung Neoplasms/veterinary , Administration, Inhalation , Aerosols , Animals , Dogs , Drug Evaluation, Preclinical/methods , HumansABSTRACT
PURPOSE: The purpose of this research was to determine whether insulin-like growth factor (IGF) suppression, using a long-acting analogue of somatostatin (OncoLAR, octreotide pamoate long-acting release), will decrease chemotherapy resistance by eliminating an important survival signal to osteosarcoma (OSA) cells in a relevant naturally occurring cancer model. EXPERIMNETAL DESIGN: We conducted a randomized, blinded, placebo-controlled preclinical study in pet dogs with naturally occurring OSA. The study compared primary tumor necrosis and apoptosis, and survival of pet dogs receiving OncoLAR and carboplatin chemotherapy compared with dogs receiving placebo and carboplatin. RESULTS: Dogs receiving OncoLAR had suppression of serum IGF levels by approximately 43% without toxicity. No differences in primary tumor necrosis, apoptosis, tumor IGF mRNA expression, or survival were seen between the dogs receiving OncoLAR plus chemotherapy compared with OncoLAR alone. CONCLUSION: The suppression of IGF levels by the extent and/or duration achieved in the trial was not sufficient to improve chemotherapy-related antitumor effects in pet dogs with OSA.